The largest and most thorough study of glucagon-like peptide-1 (GLP-1) receptor agonists regarding kidney and cardiovascular results indicates that they offer substantial advantages for individuals both with and without diabetes.
Study reveals that widely used diabetes and obesity medications also provide kidney protection.
